In accordance with Anika’s commitment to return capital to shareholders while maintaining the flexibility to execute on strategic growth objectives, the Company is commencing a $15 million 10b5-1 share repurchase which it expects to complete by June 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK:
- Anika Therapeutics reports Q3 adjusted EPS 4c vs. 7c last year
- Is ANIK a Buy, Before Earnings?
- Anika Therapeutics’ Integrity Implant System Study: A Market Game Changer?
- Anika Therapeutics: Undervalued Stock with Potential Upside Amidst Execution Challenges